Neuren Pharmaceuticals (DB:NK9) - Stock Price, News & Analysis

NK9 Stock Overview

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NK9 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 3.9% below our estimate of its fair value

Earnings are forecast to grow 4.6% per year

Earnings grew by 113.1% over the past year

Analysts in good agreement that stock price will rise by 73.9%

Risk Analysis

Volatile share price over the past 3 months

Neuren Pharmaceuticals Limited Competitors

Dermapharm Holding

XTRA:DMP

€1.9b

PharmaSGP Holding

XTRA:PSG

€254.2m

MPH Health Care

DB:93M1

€102.8m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for Neuren Pharmaceuticals
Historical stock prices
Current Share Price	AU$9.95
52 Week High	AU$12.31
52 Week Low	AU$7.55
Beta	2.13
11 Month Change	9.34%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-19.15%

Recent updates

Shareholder Returns

	NK9	DE Pharmaceuticals	DE Market
7D	21.3%	3.1%	4.5%
1Y	n/a	-12.1%	13.4%

Return vs Industry: Insufficient data to determine how NK9 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how NK9 performed against the German Market.

Price Volatility

Is NK9's price volatile compared to industry and market?
NK9 volatility
NK9 Average Weekly Movement	9.0%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: NK9 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NK9's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Jon Pilcher	www.neurenpharma.com

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.

Neuren Pharmaceuticals Limited Fundamentals Summary

How do Neuren Pharmaceuticals's earnings and revenue compare to its market cap?
NK9 fundamental statistics
Market cap	€1.21b
Earnings (TTM)	€72.54m
Revenue (TTM)	€119.58m

16.6x

P/E Ratio

10.1x

P/S Ratio

Is NK9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NK9 income statement (TTM)
Revenue	AU$193.34m
Cost of Revenue	AU$32.90m
Gross Profit	AU$160.44m
Other Expenses	AU$43.15m
Earnings	AU$117.29m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.92
Gross Margin	82.98%
Net Profit Margin	60.67%
Debt/Equity Ratio	0%

How did NK9 perform over the long term?

See historical performance and comparison

Neuren Pharmaceuticals DB:NK9 Stock Report